ClinicalTrials.gg
Not yet recruitingNCT07449286Updated Mar 4, 2026

IFN-α in Relapse Prevention.

A Phase 2 interventional study of IFN-α in Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Peking University People's Hospital. Not yet recruiting at 1 site in China. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Peking University People's Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital — 15 open to participants now, 16 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · Peking University People's Hospital.

Planned enrollment
5th of 17
100 · median 52
Started
2026
with 6 others
Phase 2
5 of 20
4 open now
Primary completion
2026-12
later than 6 of 15 live
Registered
15th of 20
by date

Among the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, this one is the 5th largest by planned enrollment of the 17 interventional ones that give a count, is one of 7 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 6 of the 15 other live ones, and was the 15th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

15 of the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, or all of them as a file.
02

Study summary

To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

03

Conditions studied

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes

Keywords

  • IFN-α
  • Preventing relapse
  • allo-HSCT
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Myelodysplastic syndrome (MDS) diagnosed according to the 2022 International Consensus Classification of Myeloid Neoplasms and Acute Leukemia (2022ICC) criteria, acute myeloid leukemia (AML) with TP53 mutation (unrestricted remission status), minimal residual disease (MRD) monitored by flow cytometry within 2 months after receiving the first hematopoietic stem cell transplantation Negative patients
  2. Male or female, aged 12-65 years
  3. score >60, estimated survival time >3 months
  4. No history of severe (GVHD), uncontrolled

    GVHD, or severe systemic organ dysfunction:

    1. (ANC) greater than 0.5×109/L
    2. Creatinine \< 1.5mg/dL
    3. Cardiac ejection index >55%
  5. Signed .

Exclusion criteria

Exclusion Criteria:

  1. severe cardiac, renal, or liver dysfunction
  2. combined with other malignant tumors requiring treatment
  3. inability to understand or adhere to the study protocol due to clinical symptoms of brain dysfunction or severe mental illness
  4. patients who are unable to complete the necessary treatment plan and follow-up observation
  5. patients with severe acute anaphylaxis
  6. clinically uncontrolled severe life-threatening infections
  7. patients enrolled in other clinical trials
  8. other reasons considered by the investigator to be inappropriate for clinical trial participants.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    IFN-α application in TP53+ myeloid malignancy

    Drug: IFN-α

Interventions

  • DrugIFN-α

    Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and * 2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon- α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day * 100 after transplantation. The dose of interferon- α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.

06

What researchers measure

Primary outcomes

  1. The incidence of relapse

    Disease relapse was defined as blasts ≥ 5% post transplantation

    Time frame: 1 year post HSCT

Secondary outcomes

  1. The incidence of positive minimal residual disease post allo-HSCT

    Positive MRD was defined as leukemia-associated immunophenotyping (LAIPs) by flow cytometry

    Time frame: 1 year post HSCT

  2. The incidence of acute and chronic graft versus host disease (GvHD)

    The severity of acute GvHD (aGvHD) and chronic GvHD (cGvHD) was evaluated according to standard criteria.

    Time frame: aGvHD within 100 days and cCvHD within 1 year

  3. The incidence of non-relapse mortality

    The incidence of non-relapse mortality

    Time frame: 1 year post HSCT

  4. The probability of progression free survival

    Survival without disease progression

    Time frame: 1 year post HSCT

  5. The probability of overall survival (OS)

    OS was defined as the time from transplantation to death from any cause or to the last follow-up.

    Time frame: 1 year post HSCT

07

Study locations

1 site
  • Peking University People's Hospital, Peking University Institute of Hematology
    Beijing, Beijing Municipality 100044, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 9 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 4, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07449286
Collaborators
Aerospace Medical Center, LU DAOPEI MEDICAL, Nanfang Hospital, Southern Medical University, Zhejiang University
Responsible party
Xiao-Jun Huang (Professor, Peking University People's Hospital) — Principal investigator
First posted
Mar 4, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Yu Wang
Contact
ywyw3172@sina.com
010-88326000
Xiaojun Huang
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion